<DOC>
	<DOCNO>NCT00302211</DOCNO>
	<brief_summary>The purpose multi-center international trial evaluate safety effectiveness add iloprost placebo ( inactive substance contains active study drug ) sildenafil therapy pulmonary arterial hypertension ( PAH ) . The study also examine whether patient sildenafil reduce number iloprost inhalation approve 6 dos per day 4 dos per day .</brief_summary>
	<brief_title>The `` VISION '' Trial : Ventavis Inhalation With Sildenafil Improve Optimize Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Aged 1285 year ; either gender . Confirmed PAH due idiopathic pulmonary arterial hypertension ( IPAH ) familial pulmonary arterial hypertension ( FPAH ) . 6minute walk distance ( 6MWD ) 100450 meter screen . On stable dose sildenafil , without Bosentan . Any treatment PAH prostacyclins , prostacyclin analogue , endothelin1 antagonist , phosphodiesterase5 ( PDE5 ) inhibitor sildenafil within past 12 week . Pulmonary hypertension due condition state inclusion criterion . Additional PAH medication add within past 12 week</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>PAH</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>